Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001–2010

被引：0
|
作者：
MerriKay Oleen-Burkey
Anissa Cyhaniuk
Eric Swallow
机构：
[1] Outcomes Scribe,
[2] LLC,undefined
[3] Formerly,undefined
[4] Health Economics and Outcomes Research,undefined
[5] Teva Pharmaceuticals,undefined
[6] OptumInsight Life Sciences,undefined
来源：
BMC Neurology | / 14卷
关键词：
Multiple sclerosis; Disease-modifying therapy; Persistence; Treatment gaps; Therapy re-initiaton; Therapy switching; Therapy discontinuation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Treatment algorithms of relapsing multiple sclerosis: an exploration based on the available disease-modifying therapies in China
    Guo, Jun
    Wu, Jiayong
    Wang, Lihua
    Liu, Hongbo
    Wu, Xiaomu
    Yang, Huan
    Li, Wenyu
    Wang, Honghao
    Bu, Bitao
    Yang, Chunsheng
    Zhou, Hongyu
    Guo, Shougang
    Zhao, Yinan
    Wang, Zhanhang
    Li, Chunyang
    Tian, De-Cai
    Chen, Sheng
    Xue, Huiru
    Zhang, Yanlin
    Xu, Yongfeng
    Liang, Hui
    Wu, Zhe
    Zhang, Yu
    Dong, Qiang
    Wang, Jiawei
    Quan, Chao
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2024, 17
  • [32] Persistence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in the German NeuroTransData registry
    Braune, Stefan
    Dirks, Petra
    Colloud, Seya
    Davies, Evan
    Wang, Qing
    Heer, Yanic
    Zurcher, Mel
    Sun, Diana
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 631 - 632
  • [33] The Effect of Disease-Modifying Therapy on Disability Status in a Longitudinal Retrospective Analysis of a Multiple Sclerosis Center Database
    Wells, Michael J.
    Kirzinger, Stephen S.
    Cobbs, Gary A.
    NEUROLOGY, 2009, 72 (11) : A241 - A241
  • [34] Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis
    Charles Dolladille
    Basile Chrétien
    Laure Peyro-Saint-Paul
    Joachim Alexandre
    Olivier Dejardin
    Sophie Fedrizzi
    Gilles Defer
    Neurotherapeutics, 2021, 18 : 1657 - 1664
  • [35] Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis
    Dolladille, Charles
    Chretien, Basile
    Peyro-Saint-Paul, Laure
    Alexandre, Joachim
    Dejardin, Olivier
    Fedrizzi, Sophie
    Defer, Gilles
    NEUROTHERAPEUTICS, 2021, 18 (03) : 1657 - 1664
  • [36] Price analysis of multiple sclerosis disease-modifying therapies marketed in the United States
    Bin Sawad, Aseel
    Seoane-Vazquez, Enrique
    Rodriguez-Monguio, Rosa
    Turkistani, Fatema
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (11) : 1783 - 1788
  • [37] Analysis of Reported Deaths While Exposed to Disease-Modifying Therapies for Multiple Sclerosis
    Hooshmand, Sam
    Carlisle, Nicola
    Maynard, Michelle
    Hoffman, Leah
    Obeidat, Ahmed
    NEUROLOGY, 2020, 94 (15)
  • [38] Statistical analysis of clinical endpoints in studies of disease-modifying therapies for multiple sclerosis
    Cutter, Gary
    Sormani, Maria
    Pace, Amy
    Zhang, Hao
    NEUROLOGY, 2008, 70 (11) : A104 - A104
  • [39] Use of multiple sclerosis disease-modifying therapies during pregnancy in France from 2010 to 2021
    Swital, Morgane
    Drouin, Jerome
    Miranda, Sara
    Botton, Jeremie
    Dray-Spira, Rosemary
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 526 - 527
  • [40] Swiss Analysis of Multiple Sclerosis: A Multicenter, Non-Interventional, Retrospective Cohort Study of Disease-Modifying Therapies
    Gobbi, Claudio
    Zecca, Chiara
    Linnebank, Michael
    Mueller, Stefanie
    You, Xiaojun
    Meier, Rosetta
    Borter, Emmanuela
    Traber, Martin
    EUROPEAN NEUROLOGY, 2013, 70 (1-2) : 35 - 41
12345